{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T01:03:33Z","timestamp":1772759013476,"version":"3.50.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2011,6,7]],"date-time":"2011-06-07T00:00:00Z","timestamp":1307404800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2011,11]]},"DOI":"10.1007\/s10067-011-1779-1","type":"journal-article","created":{"date-parts":[[2011,6,6]],"date-time":"2011-06-06T02:05:57Z","timestamp":1307325957000},"page":"1447-1454","source":"Crossref","is-referenced-by-count":40,"title":["Outcomes of switching anti-TNF drugs in rheumatoid arthritis\u2014a study based on observational data from the Finnish Register of Biological Treatment (ROB-FIN)"],"prefix":"10.1007","volume":"30","author":[{"given":"Liisa M.","family":"Virkki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heikki","family":"Valleala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuya","family":"Takakubo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorma","family":"Vuotila","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heikki","family":"Relas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riitta","family":"Komulainen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riitta","family":"Koivuniemi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Urpo","family":"Yli-Kerttula","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markku","family":"Mali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susanna","family":"Sihvonen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maija-Liisa","family":"Krogerus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eero","family":"Jukka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satu","family":"Nyrhinen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yrj\u00f6 T.","family":"Konttinen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan C.","family":"Nordstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,6,7]]},"reference":[{"key":"1779_CR1","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1136\/ard.2003.014878","volume":"63","author":"MH Buch","year":"2004","unstructured":"Buch MH, Conaghan PG, Quinn MA, Bingham SJ, Veale D, Emery P (2004) True infliximab resistance in rheumatoid arthritis: a role for lymphotoxin alpha? Ann Rheum Dis 63:1344\u20131346","journal-title":"Ann Rheum Dis"},{"key":"1779_CR2","doi-asserted-by":"crossref","first-page":"3217","DOI":"10.1002\/art.24913","volume":"60","author":"R Klaasen","year":"2009","unstructured":"Klaasen R, Thurlings RM, Wijbrandts CA, van Kuijk AW, Baeten D, Gerlag DM, Tak PP (2009) The relationship between synovial lymphocyte aggregates and the clinical response to infliximab in rheumatoid arthritis: a prospective study. Arthritis Rheum 60:3217\u20133224","journal-title":"Arthritis Rheum"},{"key":"1779_CR3","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.pharmthera.2007.10.001","volume":"117","author":"D Tracey","year":"2008","unstructured":"Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP (2008) Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 117:244\u2013279","journal-title":"Pharmacol Ther"},{"key":"1779_CR4","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1093\/rheumatology\/keh483","volume":"44","author":"S Mpofu","year":"2005","unstructured":"Mpofu S, Fatima F, Moots RJ (2005) Anti-TNF-alpha therapies: they are all the same (aren\u2019t they?). Rheumatology (Oxford) 44:271\u2013273","journal-title":"Rheumatology (Oxford)"},{"key":"1779_CR5","doi-asserted-by":"crossref","first-page":"591","DOI":"10.2165\/00003495-200868050-00003","volume":"68","author":"JR Lutt","year":"2008","unstructured":"Lutt JR, Deodhar A (2008) Rheumatoid arthritis: strategies in the management of patients showing an inadequate response to TNFalpha antagonists. Drugs 68:591\u2013606","journal-title":"Drugs"},{"issue":"Suppl 1","key":"1779_CR6","doi-asserted-by":"crossref","first-page":"i2","DOI":"10.1136\/ard.2009.123885","volume":"69","author":"DE Furst","year":"2010","unstructured":"Furst DE, Keystone EC, Fleischmann R, Mease P, Breedveld FC, Smolen JS, Kalden JR, Braun J, Bresnihan B, Burmester GR, De Benedetti F, D\u00f6rner T, Emery P, Gibofsky A, Kavanaugh A, Kirkham B, Schiff MH, Sieper J, Singer N, Van Riel PL, Weinblatt ME, Weisman MH, Winthrop K (2010) Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009. Ann Rheum Dis 69(Suppl 1):i2\u2013i29","journal-title":"Ann Rheum Dis"},{"key":"1779_CR7","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1136\/ard.2003.009589","volume":"62","author":"R Vollenhoven van","year":"2003","unstructured":"van Vollenhoven R, Harju A, Brannemark S, Klareskog L (2003) Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumour necrosis factor alpha blockers can make sense. Ann Rheum Dis 62:1195\u20131198","journal-title":"Ann Rheum Dis"},{"key":"1779_CR8","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.jbspin.2004.07.009","volume":"71","author":"O Brocq","year":"2004","unstructured":"Brocq O, Albert C, Roux C, Gerard D, Breuil V, Ziegler LE (2004) Adalimumab in rheumatoid arthritis after failed infliximab and\/or etanercept therapy: experience with 18 patients. Joint Bone Spine 71:601\u2013603","journal-title":"Joint Bone Spine"},{"key":"1779_CR9","first-page":"607","volume":"63","author":"Y Yazici","year":"2004","unstructured":"Yazici Y, Erkan D (2004) Do etanercept-naive patients with rheumatoid arthritis respond better to infliximab than patients for whom etanercept has failed? Ann Rheum Dis 63:607\u2013608","journal-title":"Ann Rheum Dis"},{"key":"1779_CR10","first-page":"795","volume":"23","author":"G Cohen","year":"2005","unstructured":"Cohen G, Courvoisier N, Cohen JD, Zaltni S, Sany J, Combe B (2005) The efficiency of switching from infliximab to etanercept and vice-versa in patients with rheumatoid arthritis. Clin Exp Rheumatol 23:795\u2013800","journal-title":"Clin Exp Rheumatol"},{"key":"1779_CR11","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1080\/03009740510026887","volume":"34","author":"MC Wick","year":"2005","unstructured":"Wick MC, Ernestam S, Lindblad S, Bratt J, Klareskog L, van Vollenhoven RF (2005) Adalimumab (Humira) restores clinical response in patients with secondary loss of efficacy from infliximab (Remicade) or etanercept (Enbrel): results from the STURE registry at Karolinska University Hospital. Scand J Rheumatol 34:353\u2013358","journal-title":"Scand J Rheumatol"},{"key":"1779_CR12","doi-asserted-by":"crossref","first-page":"R29","DOI":"10.1186\/ar1881","volume":"8","author":"JJ Gomez-Reino","year":"2006","unstructured":"Gomez-Reino JJ, Carmona L (2006) Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period. Arthritis Res Ther 8:R29","journal-title":"Arthritis Res Ther"},{"key":"1779_CR13","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1136\/ard.2005.039099","volume":"65","author":"SN Nikas","year":"2006","unstructured":"Nikas SN, Voulgari PV, Alamanos Y, Papadopoulos CG, Venetsanopoulos AI, Georgiadis AN, Drosos AA (2006) Efficacy and safety of switching from infliximab to adalimumab: a comparative controlled study. Ann Rheum Dis 65:257\u2013260","journal-title":"Ann Rheum Dis"},{"key":"1779_CR14","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1093\/rheumatology\/kel054","volume":"45","author":"E Solau-Gervais","year":"2006","unstructured":"Solau-Gervais E, Laxenaire N, Cortet B, Dubucquoi S, Duquesnoy B, Flipo RM (2006) Lack of efficacy of a third tumour necrosis factor alpha antagonist after failure of a soluble receptor and a monoclonal antibody. Rheumatology (Oxford) 45:1121\u20131124","journal-title":"Rheumatology (Oxford)"},{"key":"1779_CR15","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1093\/rheumatology\/kem091","volume":"46","author":"S Bombardieri","year":"2007","unstructured":"Bombardieri S, Ruiz AA, Fardellone P, Geusens P, McKenna F, Unnebrink K, Oezer U, Kary S, Kupper H, Burmester GR, Research in Active Rheumatoid Arthritis (ReAct) Study Group (2007) Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice. Rheumatology (Oxford) 46:1191\u20131199","journal-title":"Rheumatology (Oxford)"},{"key":"1779_CR16","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1002\/art.22617","volume":"57","author":"MH Buch","year":"2007","unstructured":"Buch MH, Bingham SJ, Bejarano V, Bryer D, White J, Reece R, Quinn M, Emery P (2007) Therapy of patients with rheumatoid arthritis: outcome of infliximab failures switched to etanercept. Arthritis Rheum 57:448\u2013453","journal-title":"Arthritis Rheum"},{"key":"1779_CR17","first-page":"85","volume":"25","author":"E Poi Di","year":"2007","unstructured":"Di Poi E, Perin A, Morassi MP, Del Frate M, Ferraccioli GF, De Vita S (2007) Switching to etanercept in patients with rheumatoid arthritis with no response to infliximab. Clin Exp Rheumatol 25:85\u201387","journal-title":"Clin Exp Rheumatol"},{"key":"1779_CR18","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1136\/ard.2006.068304","volume":"66","author":"DE Furst","year":"2007","unstructured":"Furst DE, Gaylis N, Bray V, Olech E, Yocum D, Ritter J, Weisman M, Wallace DJ, Crues J, Khanna D, Eckel G, Yeilding N, Callegari P, Visvanathan S, Rojas J, Hegedus R, George L, Mamun K, Gilmer K, Troum O (2007) Open-label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: the opposite study. Ann Rheum Dis 66:893\u2013899","journal-title":"Ann Rheum Dis"},{"key":"1779_CR19","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1136\/ard.2006.054742","volume":"66","author":"E Hjardem","year":"2007","unstructured":"Hjardem E, \u00d8stergaard M, P\u00f8denphant J, Tarp U, Andersen LS, Bing J, Peen E, Lindegaard HM, Ringsdal VS, R\u00f8dgaard A, Sk\u00f8t J, Hansen A, Mogensen HH, Unkerskov J, Hetland ML (2007) Do rheumatoid arthritis patients in clinical practice benefit from switching from infliximab to a second tumor necrosis factor alpha inhibitor? Ann Rheum Dis 66:1184\u20131189","journal-title":"Ann Rheum Dis"},{"key":"1779_CR20","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/art.22331","volume":"56","author":"KL Hyrich","year":"2007","unstructured":"Hyrich KL, Lunt M, Watson KD, Symmons DP, Silman AJ (2007) Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study. Arthritis Rheum 56:13\u201320","journal-title":"Arthritis Rheum"},{"key":"1779_CR21","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1136\/ard.2006.058776","volume":"66","author":"F Iannone","year":"2007","unstructured":"Iannone F, Trotta F, Montecucco C, Giacomelli R, Galeazzi M, Matucci-Cerinic M, Ferri C, Cutolo M, Maria Bambara L, Triolo G, Ferraccioli G, Valentini G, Lapadula G (2007) Etanercept maintains the clinical benefit achieved by infliximab in patients with rheumatoid arthritis who discontinued infliximab because of side effects. Ann Rheum Dis 66:249\u2013252","journal-title":"Ann Rheum Dis"},{"key":"1779_CR22","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1093\/rheumatology\/ken034","volume":"47","author":"JA Karlsson","year":"2008","unstructured":"Karlsson JA, Kristensen LE, Kapetanovic MC, G\u00fclfe A, Saxne T, Geborek P (2008) Treatment response to a second or third TNF-inhibitor in RA: results from the South Swedish Arthritis Treatment Group Register. Rheumatology (Oxford) 47:507\u2013513","journal-title":"Rheumatology (Oxford)"},{"key":"1779_CR23","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.3899\/jrheum.090054","volume":"36","author":"M Blom","year":"2009","unstructured":"Blom M, Kievit W, Fransen J, Kuper IH, den Broeder AA, De Gendt CM, Jansen TL, Brus HL, van de Laar MA, van Riel PL (2009) The reason for discontinuation of the first tumor necrosis factor (TNF) blocking agent does not influence the effect of a second TNF blocking agent in patients with rheumatoid arthritis. J Rheumatol 36:2171\u20132177","journal-title":"J Rheumatol"},{"key":"1779_CR24","first-page":"540","volume":"27","author":"F Conti","year":"2009","unstructured":"Conti F, Scrivo R, Spinelli FR, Truglia S, Magrini L, Di Franco M, Ceccarelli F, Valesini G (2009) Outcome in patients with rheumatoid arthritis switching TNF-alpha antagonists: a single center, observational study over an 8-year period. Clin Exp Rheumatol 27:540\u2013541","journal-title":"Clin Exp Rheumatol"},{"key":"1779_CR25","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/S0140-6736(09)60506-7","volume":"374","author":"JS Smolen","year":"2009","unstructured":"Smolen JS, Kay J, Doyle MK, Landew\u00e9 R, Matteson EL, Wollenhaupt J, Gaylis N, Murphy FT, Neal JS, Zhou Y, Visvanathan S, Hsia EC, Rahman MU, for the GO-AFTER study investigators (2009) Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. Lancet 374:210\u2013221","journal-title":"Lancet"},{"key":"1779_CR26","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1007\/s00296-005-0097-9","volume":"26","author":"L Konttinen","year":"2006","unstructured":"Konttinen L, Honkanen V, Uotila T, P\u00f6ll\u00e4nen J, Waahtera M, Romu M, Puolakka K, Vasala M, Karjalainen A, Luukkainen R, Nordstr\u00f6m DC (2006) Biological treatment in rheumatic diseases: results from a longitudinal surveillance: adverse events. Rheumatol Int 26:916\u2013922","journal-title":"Rheumatol Int"},{"key":"1779_CR27","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1007\/s10067-006-00243-0","volume":"25","author":"L Konttinen","year":"2006","unstructured":"Konttinen L, Kankaanp\u00e4\u00e4 E, Luosuj\u00e4rvi R, Bl\u00e5field H, Vuori K, Hakala M, Rantalaiho V, Savolainen E, Uutela T, Nordstr\u00f6m D (2006) Effectiveness of anakinra in rheumatic disease in patients naive to biological drugs or previously on TNF blocking drugs: an observational study. Clin Rheumatol 25:882\u2013884","journal-title":"Clin Rheumatol"},{"key":"1779_CR28","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1007\/s00296-005-0054-7","volume":"26","author":"DC Nordstr\u00f6m","year":"2006","unstructured":"Nordstr\u00f6m DC, Konttinen L, Korpela M, Tiippana-Kinnunen T, Eklund K, Forsberg S, Ilva K, Kaipiainen-Sepp\u00e4nen O, Malmi T, Yl\u00e4-Kerttula T, Honkanen V (2006) Classic disease modifying anti-rheumatic drugs (DMARDs) in combination with infliximab. The Finnish experience. Rheumatol Int 26:741\u2013748","journal-title":"Rheumatol Int"},{"key":"1779_CR29","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1007\/s10067-007-0574-5","volume":"26","author":"L Konttinen","year":"2007","unstructured":"Konttinen L, Tuompo R, Uusitalo T, Luosuj\u00e4rvi R, Laiho K, L\u00e4hteenm\u00e4ki J, Puurtinen-Vilkki M, Lanteri R, Kortelainen S, Karilainen H, Varjolahti-Lehtinen T, Nordstr\u00f6m D (2007) Anti-TNF therapy in the treatment of ankylosing spondylitis: the Finnish experience; ROB-FIN Study Group. Clin Rheumatol 26:1693\u20131700","journal-title":"Clin Rheumatol"},{"key":"1779_CR30","first-page":"1059","volume":"26","author":"LM Virkki","year":"2008","unstructured":"Virkki LM, Konttinen YT, Peltomaa R, Suontama K, Saario R, Immonen K, J\u00e4ntti J, Tuomiranta T, Nyk\u00e4nen P, H\u00e4meenkorpi R, Heikkil\u00e4 S, Isom\u00e4ki P, Nordstr\u00f6m D (2008) Cost-effectiveness of infliximab in the treatment of rheumatoid arthritis in clinical practice. Clin Exp Rheumatol 26:1059\u20131066","journal-title":"Clin Exp Rheumatol"},{"key":"1779_CR31","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.3899\/jrheum.091477","volume":"37","author":"LM Virkki","year":"2010","unstructured":"Virkki LM, Sumathikutty BC, Aarnio M, Valleala H, Heikkil\u00e4 R, Kauppi M, Karstila K, Piril\u00e4 L, Ekman P, Salomaa S, Romu M, Sepp\u00e4l\u00e4 J, Niinisalo H, Konttinen YT, Nordstr\u00f6m DC (2010) Biological therapy for psoriatic arthritis in clinical practice: outcomes up to 2\u00a0years. J Rheumatol 37:2362\u20132368","journal-title":"J Rheumatol"},{"key":"1779_CR32","unstructured":"Hakala M, Hannonen P, Helve T, Korpela M, Mattila K, M\u00f6ttonen T, Varis T (updated 2009) Rheumatoid arthritis. Current Care guideline 2003. www.kaypahoito.fi . Accessed 14 Apr 2011"},{"key":"1779_CR33","first-page":"2356","volume":"31","author":"B Haraoui","year":"2004","unstructured":"Haraoui B, Keystone EC, Thorne JC, Pope JE, Chen I, Asare CG, Leff JA (2004) Clinical outcomes of patients with rheumatoid arthritis after switching from infliximab to etanercept. J Rheumatol 31:2356\u20132359","journal-title":"J Rheumatol"},{"key":"1779_CR34","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1002\/art.21671","volume":"54","author":"GJ Wolbink","year":"2006","unstructured":"Wolbink GJ, Vis M, Lems W, Voskuyl AE, de Groot E, Nurmohamed MT, Stapel S, Tak PP, Aarden L, Dijkmans B (2006) Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum 54:711\u2013715","journal-title":"Arthritis Rheum"},{"key":"1779_CR35","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1093\/rheumatology\/kem075","volume":"46","author":"MH Buch","year":"2007","unstructured":"Buch MH, Bingham SJ, Bryer D, Emery P (2007) Long-term infliximab treatment in rheumatoid arthritis: subsequent outcome of initial responders. Rheumatology (Oxford) 46:1153\u20131156","journal-title":"Rheumatology (Oxford)"},{"key":"1779_CR36","doi-asserted-by":"crossref","first-page":"3782","DOI":"10.1002\/art.22214","volume":"54","author":"K Bendtzen","year":"2006","unstructured":"Bendtzen K, Geborek P, Svenson M, Larsson L, Kapetanovic MC, Saxne T (2006) Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab. Arthritis Rheum 54:3782\u20133789","journal-title":"Arthritis Rheum"},{"key":"1779_CR37","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1136\/ard.2008.092833","volume":"68","author":"TR Radstake","year":"2009","unstructured":"Radstake TR, Svenson M, Eijsbouts AM, van den Hoogen FH, Enevold C, van Riel PL, Bendtzen K (2009) Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis. Ann Rheum Dis 68:1739\u20131745","journal-title":"Ann Rheum Dis"},{"key":"1779_CR38","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1007\/s10067-008-0866-4","volume":"27","author":"AE Bijl van der","year":"2008","unstructured":"van der Bijl AE, Breedveld FC, Antoni CE, Kalden JR, Kary S, Burmester GR, Beckmann C, Unnebrink K, Kupper H (2008) An open-label pilot study of the effectiveness of adalimumab in patients with rheumatoid arthritis and previous infliximab treatment: relationship to reasons for failure and anti-infliximab antibody status. Clin Rheumatol 27:1021\u20131028","journal-title":"Clin Rheumatol"},{"key":"1779_CR39","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1136\/ard.2006.065615","volume":"66","author":"GM Bartelds","year":"2007","unstructured":"Bartelds GM, Wijbrandts CA, Nurmohamed MT, Stapel S, Lems WF, Aarden L, Dijkmans BA, Tak PP, Wolbink GJ (2007) Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis 66:921\u2013926","journal-title":"Ann Rheum Dis"},{"key":"1779_CR40","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1136\/ard.2003.016824","volume":"63","author":"AP Rozin","year":"2004","unstructured":"Rozin AP (2004) Infliximab efficiency and failure. Ann Rheum Dis 63:751\u2013752","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 1","key":"1779_CR41","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.semarthrit.2005.01.005","volume":"34","author":"PJ Anderson","year":"2005","unstructured":"Anderson PJ (2005) Tumor necrosis factor inhibitors: clinical implications of their different immunogenicity profiles. Semin Arthritis Rheum 34(Suppl 1):19\u201322","journal-title":"Semin Arthritis Rheum"},{"key":"1779_CR42","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1136\/ard.2009.112847","volume":"69","author":"GM Bartelds","year":"2010","unstructured":"Bartelds GM, Wijbrandts CA, Nurmohamed MT, Stapel S, Lems WF, Aarden L, Dijkmans BA, Tak PP, Wolbink GJ (2010) Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study. Ann Rheum Dis 69:817\u2013821","journal-title":"Ann Rheum Dis"},{"key":"1779_CR43","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1136\/ard.2008.098111","volume":"67","author":"JS Smolen","year":"2008","unstructured":"Smolen JS, Weinblatt ME (2008) When patients with rheumatoid arthritis fail tumour necrosis factor inhibitors: what is the next step? Ann Rheum Dis 67:1497\u20131498","journal-title":"Ann Rheum Dis"},{"key":"1779_CR44","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/nrrheum.2010.45","volume":"6","author":"E Villeneuve","year":"2010","unstructured":"Villeneuve E, Haraoui B (2010) To switch or to change class\u2014the biologic dilemma in rheumatoid arthritis. Nat Rev Rheumatol 6:301\u2013305","journal-title":"Nat Rev Rheumatol"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-011-1779-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-011-1779-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-011-1779-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T08:51:50Z","timestamp":1559119910000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-011-1779-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,6,7]]},"references-count":44,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2011,11]]}},"alternative-id":["1779"],"URL":"https:\/\/doi.org\/10.1007\/s10067-011-1779-1","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,6,7]]}}}